Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 101–200 of 1,004
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, R. B., Adib, G., Adler, R. A., Åkesson, K. E., Alexander, I. M., Amenta, K. C., Blank, R. D., Brox, W. T., Carmody, E. E., Chapman-Novakofski, K., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3877 · Cited by 242
The challenges of diagnosing osteoporosis and the limitations of currently available tools
Choksi, P., Jepsen, K. J., & Clines, G. A. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0062-7 · Cited by 240
Osteoporosis and fractures in women: the burden of disease
Lorentzon, M., Johansson, H., Harvey, N. C., Liu, E., Vandenput, L., McCloskey, E. V., & Kanis, J. A. (2022) · Climacteric · doi:10.1080/13697137.2021.1951206 · Cited by 241
Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1801 · Cited by 243
Self-citationBlack, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Self-citationShapiro, C. L., Van Poznak, C., Lacchetti, C., Kirshner, J., Eastell, R., Gagel, R., Smith, S., Edwards, B. J., Frank, E., Lyman, G. H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01696 · Cited by 231
Self-citationUpdate on Osteoporosis Screening and Management
Anam, A. K., & Insogna, K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.016 · Cited by 232
Jha, S., Wang, Z., Laucis, N., & Bhattacharyya, T. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2565 · Cited by 230
Alendronate and Atrial Fibrillation
Cummings, S. R., Schwartz, A. V., & Black, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076132 · Cited by 230
Self-citationCharcot arthropathy of the foot and ankle: modern concepts and management review
Wukich, D. K., & Sung, W. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.09.004 · Cited by 228
“Black et al. (2007) studied the use of bisphosphonates for postmenopausal osteoporosis and reported that “serious atrial fibrillation occurred more frequently in the zoledronic acid [bisphosphonate] group” than in the placebo-controlled group.”
BackgroundPrevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial
Van Poznak, C., Hannon, R. A., Mackey, J. R., Campone, M., Apffelstaedt, J. P., Clack, G., Barlow, D., Makris, A., & Eastell, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5902 · Cited by 224
Self-citationEffects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure
Recker, R. R., Delmas, P. D., Halse, J., Reid, I. R., Boonen, S., García-Hernandez, P. A., Supronik, J., Lewiecki, E. M., Ochoa, L., Miller, P., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070906 · Cited by 225
“This notion is further corroborated by the biomarker profile obtained in this study.((21)) Between each dosing, markers of bone resorption and formation all exhibited increases, in keeping with preservation of remodeling capacity in bone.”
ResultSelf-citationHändel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J.-J., Brandi, M. L., Diez-Perez, A., et al. (2023) · BMJ · doi:10.1136/bmj-2021-068033 · Cited by 219
Boonen, S., Adachi, J. D., Man, Z., Cummings, S. R., Lippuner, K., Törring, O., Gallagher, J. C., Farrerons, J., Wang, A., Franchimont, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2784 · Cited by 220
Self-citationBundred, N. J., Campbell, I. D., Davidson, N., DeBoer, R. H., Eidtmann, H., Monnier, A., Neven, P., von Minckwitz, G., Miller, J. C., Schenk, N. L., et al. (2008) · Cancer · doi:10.1002/cncr.23259 · Cited by 218
Bone turnover markers: understanding their value in clinical trials and clinical practice
Civitelli, R., Armamento-Villareal, R., & Napoli, N. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0838-9 · Cited by 216
“Similar results exist for alendronate [59], and more recent data also demonstrate that zoledronic acid, administered once annually for 3 years, results in a reduction in vertebral fractures accompanied by reduction in CTX, bone ALP, and PINP levels [60].”
ResultThe epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
Baccaro, L. F., Conde, D., Costa-Paiva, L., & Pinto-Neto, A. M. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s54614 · Cited by 216
Screening for Osteoporosis: An Update for the U.S. Preventive Services Task Force
Nelson, H. D., Haney, E. M., Dana, T., Bougatsos, C., & Chou, R. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-2-201007200-00262 · Cited by 216
Lithium's effect on bone mineral density
Zamani, A., Omrani, G. R., & Nasab, M. M. (2009) · Bone · doi:10.1016/j.bone.2008.10.001 · Cited by 214
Risks and benefits of bisphosphonates
Coleman, R. E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604382 · Cited by 212
“In a recent randomised trial of IV zoledronic acid, given to treat osteoporosis, there were two possible cases of ONJ, one in the placebo arm and one in the group receiving active treatment (Black et al, 2007).”
BackgroundBisphosphonates for Osteoporosis
Favus, M. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmct1004903 · Cited by 213
Donnelly, E., Meredith, D. S., Nguyen, J. T., Gladnick, B. P., Rebolledo, B. J., Shaffer, A. D., Lorich, D. G., Lane, J. M., & Boskey, A. L. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.560 · Cited by 211
Wessel, J. H., Dodson, T. B., & Zavras, A. I. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2007.11.032 · Cited by 208
Antiresorptive therapies for osteoporosis: a clinical overview
Chen, J. S., & Sambrook, P. N. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.146 · Cited by 207
“Randomized controlled trials (RCTs) provide good evidence for the efficacy of antiresorptive therapies in preventing fracture among postmenopausal women with osteoporosis”
BackgroundOverview of treatment approaches to osteoporosis
Langdahl, B. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 207
“Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial (HORIZON) study (Black et al., 2007), was extended into the HORIZON Extension trial (Black et al.”
BackgroundInfluentialLupsa, B. C., & Insogna, K. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.05.002 · Cited by 206
“Teriparatide (brand name Forteo) Recombinant human parathyroid hormone (1-34) (teriparatide) is approved for the treatment of postmenopausal osteoporosis in women who are at high risk for fracture.”
BackgroundOsteoporosis – a current view of pharmacological prevention and treatment
Crockett, J., & Das (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s31504 · Cited by 206
“There have been a few reports of cases of treatment failure or incidence of fragility fracture in patients taking antiosteoporotic medications, particularly bisphosphonates.(64) This group of patients was categorized as nonresponsive or resistant to bisphosphonate treatment, and it would be interesting to determine wh…”
BackgroundRizzoli, R., Reginster, J.-Y., Boonen, S., Bréart, G., Diez-Perez, A., Felsenberg, D., Kaufman, J.-M., Kanis, J. A., & Cooper, C. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9499-8 · Cited by 206
“2% in the placebo group, less so after second infusion) [25, 26].”
BackgroundSelf-citationTreating osteoporosis to prevent fractures: current concepts and future developments
Lorentzon, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12873 · Cited by 203
Short-term and long-term effects of osteoporosis therapies
Reid, I. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.71 · Cited by 201
Self-citationEriksen, E. F., Díez-Pérez, A., & Boonen, S. (2014) · Bone · doi:10.1016/j.bone.2013.09.023 · Cited by 199
“This was seen in other HORIZON studies including the HORIZON PFT core study,[9] in which stroke”
BackgroundResultInfluentialSelf-citationUse of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., & Psaty, B. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.826 · Cited by 199
Self-citationYamazaki, T., Yamori, M., Ishizaki, T., Asai, K., Goto, K., Takahashi, K., Nakayama, T., & Bessho, K. (2012) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2012.06.020 · Cited by 193
“identified only 1 patient with possible ONJ among 3852 postmenopausal women during a 3-year period.(10) In their 6-year population-based cohort study using medical claims data, Wilkinson et al.”
BackgroundFracture mortality: associations with epidemiology and osteoporosis treatment
Sattui, S. E., & Saag, K. G. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.125 · Cited by 195
Lester, J. E., Dodwell, D., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., Brown, J. E., Hannon, R. A., & Coleman, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5101 · Cited by 189
Biomedical applications of bisphosphonates
Giger, E. V., Castagner, B., & Leroux, J.-C. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.032 · Cited by 187
Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy
Edwards, B. J., Hellstein, J. W., Jacobsen, P. L., Kaltman, S., Mariotti, A., & Migliorati, C. A. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0110 · Cited by 188
The Relationship between Metabolic Syndrome and Osteoporosis: A Review
Wong, S., Chin, K.-Y., Suhaimi, F., Ahmad, F., & Ima-Nirwana, S. (2016) · Nutrients · doi:10.3390/nu8060347 · Cited by 186
“Intolerance of oral bisphosphonate can be substituted with intravenous zoledronic acid [115,116].”
BackgroundEpidemiology and management of osteoporosis in the People’s Republic of China: current perspectives
Yuan, L.-Q., Lin, X., Xiong, D., Peng, Y.-Q., Sheng, Z.-F., Wu, X.-P., Wu, F., Liao, E.-Y., & Wu, X.-Y. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s54613 · Cited by 184
Management of severe osteoporosis
Miller, P. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1124856 · Cited by 185
Orwoll, E. S., Miller, P. D., Adachi, J. D., Brown, J., Adler, R. A., Kendler, D., Bucci-Rechtweg, C., Readie, A., Mesenbrink, P., & Weinstein, R. S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.119 · Cited by 185
Self-citationRozental, T. D., Makhni, E. C., Day, C. S., & Bouxsein, M. L. (2008) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/jbjs.g.01121 · Cited by 187
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis
Briot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R., Fardellone, P., Feron, J.-M., et al. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.02.014 · Cited by 183
Migliorini, F., Maffulli, N., Colarossi, G., Eschweiler, J., Tingart, M., & Betsch, M. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02678-x · Cited by 182
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00007 · Cited by 180
Sørensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D., Cummings, S. R., & Baron, J. A. (2008) · BMJ · doi:10.1136/bmj.39507.551644.be · Cited by 178
“Recently an international multicentre clinical trial reported that the intravenously administered bisphosphonate zoledronic acid, used annually, substantially reduced the risk of vertebral, hip, and other fractures.”
BackgroundSelf-citationBisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 178
Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range
El-Hajj Fuleihan, G., Bouillon, R., Clarke, B., Chakhtoura, M., Cooper, C., McClung, M., & Singh, R. J. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2536 · Cited by 176
Brufsky, A., Bundred, N., Coleman, R., Lambert-Falls, R., Mena, R., Hadji, P., Jin, L., Schenk, N., Ericson, S., & Perez, E. A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0206 · Cited by 175
The pathogenesis, diagnosis, investigation and management of osteoporosis
Sandhu, S. K., & Hampson, G. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.077842 · Cited by 172
“Antiresorptive agents such as bisphosphonates, oestrogens, selective oestrogen receptor modulators and denusomab rapidly decrease BTMs. 70 urine NTX or plasma/serum CTX, are seen after 1 month of treatment and reach a plateau from 3 months onwards.”
BackgroundMcClung, M. R., O'Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Kiel, D. P., Cavallari, I., Bonaca, M. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30346-8 · Cited by 169
Self-citationEfficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis
Bilezikian, J. P. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.003 · Cited by 170
Glover, S. J., Gall, M., Schoenborn-Kellenberger, O., Wagener, M., Garnero, P., Boonen, S., Cauley, J. A., Black, D. M., Delmas, P. D., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080703 · Cited by 167
Self-citationAbrahamsen, B., & Vestergaard, P. (2010) · Osteoporosis International · doi:10.1007/s00198-009-0957-3 · Cited by 167
“For comparison, the annual risk of hip fracture was 0.23% in the MORE study [17] and 0.83% in the HORIZON [18] prevention study.”
InfluentialDeath, Debility, and Destitution Following Hip Fracture
Tajeu, G. S., Delzell, E., Smith, W., Arora, T., Curtis, J. R., Saag, K. G., Morrisey, M. A., Yun, H., & Kilgore, M. L. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glt105 · Cited by 167
“These findings may have policy implications and are important not only because of the increased rate of long-term care dependence we find after hip fracture compared to stroke but also because of the higher degree of hip fracture prevention, up to 50%, provided by pharmacological interventions (2,17,38).”
New horizons in treatment of osteoporosis
Tabatabaei-Malazy, O., Salari, P., Khashayar, P., & Larijani, B. (2017) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-017-0167-z · Cited by 166
Hadji, P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.013 · Cited by 165
Davis, S., Simpson, E., Hamilton, J., James, M. M.-S., Rawdin, A., Wong, R., Goka, E., Gittoes, N., & Selby, P. (2020) · Health Technology Assessment · doi:10.3310/hta24290 · Cited by 164
Osteoporosis in patients with chronic kidney diseases: A systemic review
Hsu, C.-Y., Chen, L.-R., & Chen, K.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186846 · Cited by 162
“Studies evaluating the optimal diagnostic and management strategy in patients with CKD G4–5D are needed.”
BackgroundBiodistribution and Plasma Protein Binding of Zoledronic Acid
Weiss, H. M., Pfaar, U., Schweitzer, A., Wiegand, H., Skerjanec, A., & Schran, H. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021071 · Cited by 160
“sient rises in serum creatinine have been observed in a small fraction ( 1%) of patients with postmenopausal osteoporosis receiving onceyearly 5-mg doses of intravenous zoledronic acid (Black et al., 2007).”
BackgroundJansson, P.-A., Curiac, D., Lazou Ahrén, I., Hansson, F., Martinsson Niskanen, T., Sjögren, K., & Ohlsson, C. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30068-2 · Cited by 156
Austin, P. C., Manca, A., Zwarenstein, M., Juurlink, D. N., & Stanbrook, M. B. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.002 · Cited by 159
Langston, A. L., Campbell, M. K., Fraser, W. D., MacLennan, G. S., Selby, P. L., & Ralston, S. H. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090709 · Cited by 161
“There is also the potential for adverse effects such as osteonecrosis of the jaw,((34)) cardiac arrhythmia,((35,36)) and subtrochanteric fractures((37)) to occur in association with the high doses of bisphosphonates that were used in the intensive treatment arm, but we did not observe any of these complications in thi…”
BackgroundFauser, B. C. J. M., Mannaerts, B. M. J. L., Devroey, P., Leader, A., Boime, I., & Baird, D. T. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmn065 · Cited by 161
“For example, once-a-year zoledronate for the prevention and treatment of osteoporosis (Black et al., 2007), long-acting injectable risperidone for the treatment of schizophrenia (Möller, 2007) and contraceptive implants, such as etonogestrel, that provide sustained hormone release over a number of…”
BackgroundLiu, C., Kuang, X., Li, K., Guo, X., Deng, Q., & Li, D. (2020) · Food & Function · doi:10.1039/d0fo00787k · Cited by 160
Potential mediators of the mortality reduction with zoledronic acid after hip fracture
Colón-Emeric, C. S., Mesenbrink, P., Lyles, K. W., Pieper, C. F., Boonen, S., Delmas, P., Eriksen, E. F., & Magaziner, J. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090704 · Cited by 159
Self-citationOsteonecrosis of the Jaw and the Role of Bisphosphonates: A Critical Review
Silverman, S. L., & Landesberg, R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.005 · Cited by 160
Abrahamsen, B., Eiken, P., & Eastell, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1571 · Cited by 160
“Alendronate and Fracture Risk J Clin Endocrinol Metab, December 2010, 95(12):5258–5265”
BackgroundInfluentialSelf-citationThe 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml
Carmel, A. S., Shieh, A., Bang, H., & Bockman, R. S. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1868-7 · Cited by 163
2018 update of French recommendations on the management of postmenopausal osteoporosis
Briot, K., Roux, C., Thomas, T., Blain, H., Buchon, D., Chapurlat, R., Debiais, F., Feron, J. M., Gauvain, J. B., Guggenbuhl, P., et al. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.02.009 · Cited by 167
Adverse Effects of Bisphosphonates
Abrahamsen, B. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9364-1 · Cited by 187
“The first indication that bisphosphonates could cause an increased incidence of arrhythmia came from the HORIZON zoledronate trial [87].”
ResultThe kidney and bisphosphonates
Miller, P. D. (2011) · Bone · doi:10.1016/j.bone.2010.12.024 · Cited by 164
“8756-3282/$ – see front matter © 2010 Elsevier Inc. Al doi:10.1016/j.bone.2010.12.024 Please cite this article as: Miller PD, The ki a b s t r a c t a r t i c l e i n f o”
BackgroundMethodInfluentialBone Health and Osteoporosis Prevention and Treatment
MUÑOZ, M., ROBINSON, K., & Shibli-Rahhal, A. A. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000572 · Cited by 177
Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery
Sun, Y., Ye, X., Cai, M., Liu, X., Xiao, J., Zhang, C., Wang, Y., Yang, L., Liu, J., Li, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07828 · Cited by 157
Side effects of drugs for osteoporosis and metastatic bone disease
Skjødt, M. K., Frost, M., & Abrahamsen, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13759 · Cited by 173
“The antiresorptive treatments comprise selective oestrogen receptor modulators[3], bisphosphonates[4, 5], and denosumab[6], and used to include strontium[7], which has been discontinued due to side effects, and oestrogen replacement[8], generally considered unfavourable due to concerns regarding the balance in risks a…”
BackgroundLems, W. F., Dreinhöfer, K., Bischoff-Ferrari, H. A., Blauth, M., Czerwinski, E. J., da Silva, J. A. P., Herrera, A., Hoffmeyer, P. J., Kvien, T. K., Maalouf, G., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210289 · Cited by 183
“For patients with oral intolerance, dementia, malabsorption and non-compliance zoledronic acid (intravenous) 100 or denosumab (subcutaneous) 101 are alternatives.”
BackgroundUnderstanding the Mechanisms of Senile Osteoporosis: New Facts for a Major Geriatric Syndrome
Duque, G., & Troen, B. R. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01764.x · Cited by 183
Lems, W. F., & Raterman, H. G. (2017) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x17732562 · Cited by 168
Using biochemical markers of bone turnover in clinical practice
Singer, F. R., & Eyre, D. W. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.10.739 · Cited by 153
McDonald, M. M., Dulai, S. K., Godfrey, C., Amanat, N., Sztynda, T., & Little, D. G. (2008) · Bone · doi:10.1016/j.bone.2008.05.019 · Cited by 164
“Ibandronate trials have examined monthly and three monthly dosing regimens [8], and the recent trials of zoledronic acid (ZA) provide evidence that yearly dosing is of acceptable efficacy with this compound [3].”
BackgroundBisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
Kranenburg, G., Bartstra, J. W., Weijmans, M., de Jong, P. A., Mali, W. P. T. M., Verhaar, H. J. J., Visseren, F. L. J., & Spiering, W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.039 · Cited by 160
Indran, I. R., Liang, R. L. Z., Min, T., & Yong, E. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.015 · Cited by 154
Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion
Migliorini, F., Colarossi, G., Baroncini, A., Eschweiler, J., Tingart, M., & Maffulli, N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851192 · Cited by 155
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
Cosman, F., Lewiecki, E. M., Eastell, R., Ebeling, P. R., de Beur, S. M. J., Langdahl, B. L., Rhee, Y., Fuleihan, G. E., Kiel, D. P., Schousboe, J. T., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae119 · Cited by 184
Self-citationPazianas, M., & Abrahamsen, B. (2011) · Bone · doi:10.1016/j.bone.2011.01.003 · Cited by 163
THE MEDICAL MANAGEMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA: CURRENT TREATMENT CONSIDERATIONS
Kaplan, F. S., & Disorders, R. (2011) · Cited by 145
Hershman, D. L., McMahon, D. J., Crew, K. D., Cremers, S., Irani, D., Cucchiara, G., Brafman, L., & Shane, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4707 · Cited by 153
Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women
Greenspan, S. L., Perera, S., Ferchak, M. A., Nace, D. A., & Resnick, N. M. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0747 · Cited by 145
Brown, J. P., Morin, S. N., Leslie, W. D., Παπαϊωάννου, Α., Cheung, A. M., Davison, K. S., Goltzman, D., Hanley, D. A., Hodsman, A. B., Josse, R., et al. (2014) · Europe PMC (PubMed Central) · Cited by 170
Osteonecrosis of the Jaw and the Role of Macrophages
Pazianas, M. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq516 · Cited by 157
Baim, S., & Miller, P. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090203 · Cited by 143
“Based on these observations, Marx et al.(24) have suggested that dental surgery should not be undertaken until sCTX is 150 pg/ml and that BP therapy be suspended for 4–6 mo, if necessary, to attain this sCTX threshold.”
BackgroundMethodInfluentialNew Frontiers in Osteoporosis Therapy
Cheng, C., Wentworth, K. L., & Shoback, D. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-052218-020620 · Cited by 150
Harris, S. T., Blumentals, W. A., & Miller, P. D. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253717 · Cited by 141
Assael, L. A. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.003 · Cited by 144
Ing-Lorenzini, K., Desmeules, J., Plachta, O., Suva, D., Dayer, P., & Peter, R. (2009) · Drug Safety · doi:10.2165/00002018-200932090-00002 · Cited by 139
“More recently, the efficacy of zoledronic acid once yearly has also been demonstrated.([17]) No increased incidence of serious adverse effects were detected with alendronate, etidronate, risedronate or zoledronic acid, but the potential risk of upper gastrointestinal events and, less commonly, osteonecrosis of the jaw…”
BackgroundWysowski, D. K., & Greene, P. (2013) · Bone · doi:10.1016/j.bone.2013.09.008 · Cited by 149
“Despite the recognized efficacy of bisphosphonates [2–4], oral bisphosphonates reportedly have been associated with a number of rare, sometimes controversial adverse events [5] including esophagitis [6–8] and esophageal cancer [9,10], and both oral and intravenous formulations have been associated with severe musculos…”
Safety issues with bisphosphonate therapy for osteoporosis
Suresh, E., Pazianas, M., & Abrahamsen, B. (2013) · Rheumatology · doi:10.1093/rheumatology/ket236 · Cited by 149
Anastasilakis, A. D., Pepe, J., Napoli, N., Palermo, A., Magopoulos, C., Khan, A. A., Zillikens, M. C., & Body, J.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab888 · Cited by 157
Liem, I. S. L., Kammerlander, C., Suhm, N., Blauth, M., Roth, T., Gosch, M., Hoang‐Kim, A., Mendelson, D. A., Zuckerman, J. D., Leung, F. K. L., et al. (2013) · Injury · doi:10.1016/j.injury.2013.06.018 · Cited by 162
“Osteoporosis treatment has been proven to reduce the fracture risk, but compliance is poor [64,65].”
BackgroundDenosumab for the treatment of osteoporosis
Zaheer, S., LeBoff, M., & Lewiecki, E. M. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1000860 · Cited by 138
“Current FDA-approved pharmacological agents for use in osteoporosis and fracture risk reduction include bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid) [10-13], salmon calcitonin [14], estrogen therapy with or without medroxyprogesterone [15,16], raloxifene [17], conjugated estrogen/bazedo…”
Background
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.